Last reviewed · How we verify
Saline (NaCl 0,9 %) (placebo)
Normal saline (0.9% NaCl) is an isotonic solution that maintains fluid and electrolyte balance without pharmacological activity, serving as a physiological control or placebo.
Normal saline (0.9% NaCl) is an isotonic solution that maintains fluid and electrolyte balance without pharmacological activity, serving as a physiological control or placebo. Used for Placebo control in clinical trials, Fluid and electrolyte replacement (clinical use).
At a glance
| Generic name | Saline (NaCl 0,9 %) (placebo) |
|---|---|
| Also known as | placebo, NaCl, saline, Placebo Comparator |
| Sponsor | BioTissue Holdings, Inc |
| Modality | Biologic |
| Phase | FDA-approved |
Mechanism of action
Saline 0.9% is a sterile solution of sodium chloride in water that matches the osmolarity of human blood plasma. It is used clinically for fluid replacement, wound irrigation, and as a vehicle for drug delivery. In clinical trials, it serves as an inert placebo control with no active therapeutic mechanism.
Approved indications
- Placebo control in clinical trials
- Fluid and electrolyte replacement (clinical use)
Common side effects
- Minimal adverse events expected (inert placebo)
Key clinical trials
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial) (PHASE2)
- The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. (NA)
- The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males. (NA)
- Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease. (EARLY_PHASE1)
- Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol (PHASE2)
- Sedation for Non-invasive Ventilation in Blunt Chest Trauma (NA)
- Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saline (NaCl 0,9 %) (placebo) CI brief — competitive landscape report
- Saline (NaCl 0,9 %) (placebo) updates RSS · CI watch RSS
- BioTissue Holdings, Inc portfolio CI